Current research studies on the treatment of recurrent current ovarian cancer focus on new chemotherapeutic agents and biomolecular targeting agents. The role of surgery for recurrent ovarian cancer remains controversial. Abundant retrospective series report on the prolongation of survival with secondary cytoreductive surgery in recurrent ovarian cancer has been well-known. In recent reports, complete optimal secondary cytoreductive surgery in the management of the recurrent ovarian cancer presenting as isolated node metastases was feasible, and also showed a favorable result.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。